Business
Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
53% mean exon skipping
About this update from Wave Life Sciences Ltd.
[{"type":"text","content":"53% mean exon skipping and","length":48,"tagName":"div"}]